This article first appeared on GuruFocus.

Niagen Bioscience Inc (NASDAQ:NAGE) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $31.10 million, and the earnings are expected to come in at $0.02 per share. The full year 2025's revenue is expected to be $126.46 million and the earnings are expected to be $0.14 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 4 Warning Signs with ANGI.

Is NAGE fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for Niagen Bioscience Inc (NASDAQ:NAGE) have increased from $123.46 million to $126.46 million for the full year 2025 and increased from $148.23 million to $152.45 million for 2026 over the past 90 days. Earnings estimates for Niagen Bioscience Inc (NASDAQ:NAGE) have remained flat at $0.14 per share for the full year 2025 and increased from $0.24 per share to $0.27 per share for 2026 over the past 90 days.

In the previous quarter of 2025-06-30, Niagen Bioscience Inc's (NASDAQ:NAGE) actual revenue was $31.12 million, which beat analysts' revenue expectations of $28.32 million by 9.86%. Niagen Bioscience Inc's (NASDAQ:NAGE) actual earnings were $0.04 per share, which beat analysts' earnings expectations of $0.02 per share by 122.22%. After releasing the results, Niagen Bioscience Inc (NASDAQ:NAGE) was up by 2.23% in one day.

Based on the one-year price targets offered by 5 analysts, the average target price for Niagen Bioscience Inc (NASDAQ:NAGE) is $16.04 with a high estimate of $23.00 and a low estimate of $11.20. The average target implies an upside of 112.45% from the current price of $7.55.

Based on GuruFocus estimates, the estimated GF Value for Niagen Bioscience Inc (NASDAQ:NAGE) in one year is $3.29, suggesting a downside of -56.42% from the current price of $7.55.

Based on the consensus recommendation from 5 brokerage firms, Niagen Bioscience Inc's (NASDAQ:NAGE) average brokerage recommendation is currently 1.6, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.